Professor Helena Teede Leads Endocrinology Research at Monash Health

A global medical consensus has renamed Polycystic Ovary Syndrome (PCOS) to Polycystic Metabolic Ovary Syndrome (PMOS). The decision aims to more accurately reflect the systemic nature of the condition, shifting the clinical focus from the ovaries to the underlying metabolic dysfunction that drives the syndrome.

The initiative was led by Professor Helena Teede, Director of the Monash Centre for Health Research and Implementation and an endocrinologist at Monash Health in Melbourne, Australia. The consensus, reported by the European Medical Journal (EMJ), argues that the previous terminology was misleading and contributed to suboptimal patient care by centering the diagnosis on ovarian morphology rather than metabolic health.

Addressing the Misnomer of PCOS

For decades, the term Polycystic Ovary Syndrome has been the standard diagnosis for a complex endocrine disorder affecting millions of women and individuals assigned female at birth. However, the consensus led by Professor Teede highlights a significant discrepancy between the name and the physiological reality of the condition.

One primary concern is the word “polycystic.” In clinical practice, the “cysts” described in the ovaries are not true cysts but are actually underdeveloped follicles that have failed to ovulate. By labeling the condition as “polycystic,” the medical community has historically placed undue emphasis on ultrasound findings of the ovaries.

the consensus notes that not all individuals diagnosed with the syndrome possess polycystic ovaries, while some individuals with polycystic ovaries do not have the syndrome. This inconsistency suggests that ovarian appearance is a symptom rather than the root cause of the disorder.

The Centrality of Metabolic Dysfunction

The transition to Polycystic Metabolic Ovary Syndrome (PMOS) explicitly integrates the word “metabolic” to signal that the disorder is fundamentally a systemic metabolic issue. The consensus identifies insulin resistance and metabolic dysfunction as the primary drivers of the condition’s symptoms, including irregular menstrual cycles and hyperandrogenism.

Insulin resistance leads to elevated levels of insulin in the blood, which in turn stimulates the ovaries to produce excess androgens. This hormonal imbalance disrupts ovulation and leads to the physical manifestations associated with the syndrome. By renaming the condition PMOS, the global consensus seeks to prioritize the management of metabolic health—such as insulin sensitivity and glucose regulation—as the primary therapeutic goal.

Clinical and Patient Implications

The renaming is expected to influence how clinicians approach diagnosis and long-term management. Rather than relying heavily on pelvic ultrasounds to confirm “polycystic” ovaries, the PMOS framework encourages a more comprehensive metabolic screening.

This shift in terminology is also intended to reduce the stigma and confusion experienced by patients. Many patients have reported feeling that their systemic health concerns—such as weight gain, fatigue, and metabolic risk—were overlooked because the diagnosis focused almost exclusively on their reproductive organs.

By rebranding the condition as a metabolic syndrome, the medical community aims to validate the systemic nature of the patient’s experience and encourage a multidisciplinary approach to treatment. This approach typically involves endocrinologists, dietitians, and primary care providers focusing on holistic metabolic improvement rather than just symptom suppression.

Impact on Future Research

The adoption of PMOS is intended to guide future research toward the metabolic pathways of the syndrome. The consensus suggests that focusing on the “metabolic” aspect will likely lead to more effective interventions for preventing long-term complications, such as type 2 diabetes and cardiovascular disease, which are highly prevalent in this patient population.

Professor Teede and the contributing experts emphasize that this name change is not merely semantic but is a necessary evolution in medical understanding to ensure that patients receive care that addresses the root cause of their condition.